5 Deeply Discounted CEFs Paying Up To 10.2%

The article argues that closed-end funds (CEFs) trade at persistent discounts to NAV, enabling dividend investors to buy yield-supporting portfolios at 4%–14% less than intrinsic value. It highlights five CEFs with high stated yields—ranging from ~6.0% to 10.4%—including Taiwan Fund (TWN) at a ~14% discount to NAV, ClearBridge Energy Midstream Opportunity Fund (EMO) around a ~13% discount, and BlackRock Muniyield Quality (MQY) yielding ~6% monthly with a federal tax advantage for municipal exposure.

Analysis

This is mostly a flow and structure story, not a fundamental one. The incremental bid is likely to show up first in wrappers and discounts, while the operating businesses underneath ET, MPLX, TRGP, and TSM should barely notice unless the broader retail-income bid broadens enough to compress required returns across the sector. In other words: the signal is more about who is buying yield than about any change in cash generation.

The key second-order risk is leverage. Any CEF with borrowed capital becomes a hidden duration/credit trade, so a backup in rates or widening spreads can hit NAV before it shows up in distribution policy. That makes the next 1-3 months about Treasury yields and credit conditions, not about the headline yield percentage; the 6-18 month story only improves if financing costs ease enough to tighten discounts mechanically.

For TSM, the cleaner expression remains the operating company, not a Taiwan equity wrapper, because fee drag and distribution mechanics can lag the move while still exposing investors to the same semis cycle. For midstream, the sector is already well owned for yield and capital return, so any retail rotation into income CEFs is more likely to support sentiment than re-rate fundamentals. The contrarian miss is that a discount to NAV is not automatically cheap if the underlying portfolio is levered, illiquid, or structurally expensive to own.

Key Decisions for Investors

• Long TSM over any Taiwan equity CEF wrapper exposure on a 1-3 month horizon; the thesis is that direct semis participation captures the upside with less fee/leverage drag. Falsify if TSM guidance or AI capex commentary rolls over.
• Avoid chasing ET/MPLX/TRGP solely because of the income-wrapper narrative; if anything, use strength to trim. These names need volume growth or capital-return acceleration to justify multiple expansion, not a retail CEF bid.
• Use HQH as a short or underweight candidate on rallies if the 10Y Treasury backs up or credit spreads widen; leveraged healthcare income vehicles should underperform first via NAV erosion. Reassess if rates break lower and discounts begin to tighten across the CEF complex.
• Set a watch item on CEF discount behavior rather than headline yields: if discounts fail to narrow after a risk-on tape, treat the premium/discount story as a value trap and avoid initiating positions.
• If borrowing costs ease meaningfully over the next 3-6 months, rotate into the highest-quality leveraged CEFs only after discount compression begins; the better risk/reward is buying after the spread to NAV starts closing, not before.